Biotronik Will Launch Telemetry Pacemaker Following Marketing Trial
This article was originally published in The Gray Sheet
Executive Summary
Biotronik will conduct a 90-day marketing trial of its BAO3 pacemaker and Home Monitoring System before fully launching the products in the U.S. market.
You may also be interested in...
Medtronic Anticipating First Care Link FDA Approval in November
Medtronic Cardiac Rhythm Management expects its Internet-based Care Link Network patient management system to generate $250 mil. in five years.
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”